- Home
- THRD vs EFR Comparison
THRD vs EFR Comparison
Compare THRD & EFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRD
- EFR
- Stock Information
- Founded
- THRD 2019
- EFR 2003
- Country
- THRD United States
- EFR United States
- Employees
- THRD N/A
- EFR N/A
- Industry
- THRD Biotechnology: Pharmaceutical Preparations
- EFR Trusts Except Educational Religious and Charitable
- Sector
- THRD Health Care
- EFR Finance
- Exchange
- THRD Nasdaq
- EFR Nasdaq
- Market Cap
- THRD 157.7M
- EFR 384.0M
- IPO Year
- THRD 2022
- EFR N/A
- Fundamental
- Price
- THRD $3.45
- EFR $12.54
- Analyst Decision
- THRD Buy
- EFR
- Analyst Count
- THRD 3
- EFR 0
- Target Price
- THRD $14.00
- EFR N/A
- AVG Volume (30 Days)
- THRD 435.5K
- EFR 88.6K
- Earning Date
- THRD 03-25-2025
- EFR 01-01-0001
- Dividend Yield
- THRD N/A
- EFR 9.43%
- EPS Growth
- THRD N/A
- EFR N/A
- EPS
- THRD N/A
- EFR 1.69
- Revenue
- THRD N/A
- EFR N/A
- Revenue This Year
- THRD N/A
- EFR N/A
- Revenue Next Year
- THRD N/A
- EFR N/A
- P/E Ratio
- THRD N/A
- EFR $7.74
- Revenue Growth
- THRD N/A
- EFR N/A
- 52 Week Low
- THRD $3.18
- EFR $10.95
- 52 Week High
- THRD $16.94
- EFR $13.29
- Technical
- Relative Strength Index (RSI)
- THRD 30.03
- EFR 22.60
- Support Level
- THRD $3.36
- EFR $12.52
- Resistance Level
- THRD $3.65
- EFR $12.68
- Average True Range (ATR)
- THRD 0.14
- EFR 0.10
- MACD
- THRD 0.16
- EFR -0.04
- Stochastic Oscillator
- THRD 35.48
- EFR 3.00
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
About EFR Eaton Vance Senior Floating-Rate Fund of Beneficial Interest
Eaton Vance Senior Floating Rate Trust is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income. As a secondary objective, the fund intends to seek capital preservation. Its portfolio of investments consists of Software, Health Care Providers & Services, Machinery, Chemicals, Professional Services, IT Services, Hotels, Restaurants & Leisure, Capital Markets, Specialty Retail, Commercial Services & Supplies, and other areas. The trust invests in below investment grade floating rate loans, which are considered speculative because of the credit risk of their issuers.